Drug Search Results
More Filters [+]


Alternative Names: pendetide, prostascint
Latest Update: 2021-02-15
Latest Update Note: News Article

Product Description

A substance used to detect prostate cancer. It contains a monoclonal antibody that binds to prostate cells, linked to a substance that can bind radioisotopes. Capromab pendetide is combined with indium 111 and injected into the body. A gamma camera (a special camera that detects radioactivity) is used to find prostate cancer cells in the body. Capromab pendetide is a type of immunoconjugate. Also called ProstaScint. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/capromab-pendetide)

Mechanisms of Action: PSMA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Germany | Ireland | Italy

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pendetide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events